Review
Biochemistry & Molecular Biology
Brian Effer, Isabela Perez, Daniel Ulloa, Carolyn Mayer, Francisca Munoz, Diego Bustos, Claudio Rojas, Carlos Manterola, Luis Vergara-Gomez, Camila Dappolonnio, Helga Weber, Pamela Leal
Summary: Cancer is a major cause of death and disease globally, and treatment options are continuously evolving. Monoclonal antibodies (mAbs) have been considered a fundamental aspect of modern cancer therapy in immunotherapy. To avoid side effects, it is important to identify specific molecular targets or biomarkers of therapy and/or diagnosis (theragnostic) when designing an appropriate immunotherapeutic regimen for any type of cancer. Additionally, understanding the mechanisms of action of currently employed mAbs in immunotherapy is crucial. This review provides a description of therapeutic targets used in cancer immunotherapy over the past 5 years, as well as emerging targets for potential therapeutic options in mAbs application for immunotherapy. It also explores the mechanisms of action of currently employed mAbs in immunotherapy.
Review
Oncology
Jiachen Lu, Jianing Ding, Zhaoxia Liu, Tingtao Chen
Summary: Monoclonal antibody technology plays a vital role in biomedical and immunotherapy, and various techniques have been developed to generate different types of monoclonal antibodies, which have been widely used in disease research and treatment.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2022)
Review
Biotechnology & Applied Microbiology
Rafieh Bagherifar, Seyed Hossein Kiaie, Zahra Hatami, Armin Ahmadi, Abdolvahid Sadeghnejad, Behzad Baradaran, Reza Jafari, Yousef Javadzadeh
Summary: This study discusses the recent advances in cancer CIT, emphasizing the potential of chemoimmunotherapy and the role of immunotherapy and chemotherapy in CIT. Additionally, the utilization and development of nanoparticles in CIT are detailed.
JOURNAL OF NANOBIOTECHNOLOGY
(2021)
Review
Oncology
Maria Jose Bravo, Antonio Manuel Burgos-Molina, Marilina Garcia-Aranda, Maximino Redondo, Teresa Tellez
Summary: Recent research has shown that there may be a synergistic effect between kinase inhibitors and immunotherapy in treating breast cancer. Kinase inhibitors can modify the tumor microenvironment to enhance the infiltration and activation of immune cells, leading to increased efficacy of subsequent immunotherapeutic interventions. Additionally, targeting specific kinase pathways can reverse immune evasion mechanisms employed by tumor cells, making them more susceptible to immune recognition and destruction. This dual approach has the potential to improve response rates and outcomes in breast cancer patients, especially those with kinase-disrupted subtypes.
Review
Cell Biology
Giovanni Palladini, Paolo Milani, Fabio Malavasi, Giampaolo Merlini
Summary: AL amyloidosis is caused by a small B cell clone producing toxic light chains, and the addition of daratumumab to standard treatment has shown promising results in increasing hematologic response rates and organ responses. Anti-CD38 antibodies like daratumumab offer new powerful tools for treating AL amyloidosis, potentially becoming new standards of care.
Review
Oncology
Ke-Tao Jin, Bo Chen, Yu-Yao Liu, H. uan-Rong Lan, Jie-Ping Yan
Summary: Colorectal cancer is the third most common cancer globally with immunotherapy, including monoclonal antibodies and CAR-T cells, emerging as novel therapeutic approaches. Both monoclonal antibodies and CAR-T cells have beneficial anti-tumor effects on CRC by eliciting immune responses against tumor cells.
CANCER CELL INTERNATIONAL
(2021)
Article
Pharmacology & Pharmacy
Maryam Nakhjavani, Sarah Shigdar
Summary: Triple-negative breast cancer (TNBC) has the worst prognosis among breast cancer subtypes and lacks targeted therapy. Immunotherapy targeting PD-1/PD-L1 has shown promise. Aptamers, with their better tissue penetration and lower production cost compared to mAbs, present a potential pathway for PD-1/PD-L1 modulation in the future.
PHARMACOLOGICAL RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Shiu-Jau Chen, Shao-Cheng Wang, Yuan-Chuan Chen
Summary: Immunotherapy is a novel anti-cancer method that provides a better or alternative option for cancer patients. While increasingly approved for cancer treatment, it still has limitations such as low response rates in most cases. Future development should focus on biomarker discovery, new tumor targets, neoadjuvant immunotherapy, and combination with conventional therapies for more effective outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Dennis Y. Gout, Lotte S. Groen, Marjolein van Egmond
Summary: Monoclonal antibody (mAb) therapy has been successful in treating lymphomas and leukemias, but its efficacy is reduced in solid tumors due to an immune-suppressive tumor micro-environment. Antibody-cytokine fusion proteins, known as immunocytokines, provide a solution by acting as a local delivery platform and increasing the half-life of cytokines. These fusion proteins can activate cytotoxic immune cells and eliminate tumor cells. Current research focuses on exploring different antibody formats and cytokine payloads for the development of immunocytokines.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2022)
Article
Immunology
Weihuo Pan, Jianguo Zhao, Songou Zhang, Xiaozhen Chen, Wenqing Liang, Qingping Li
Summary: Immunotherapy has shown promising outcomes in the treatment of CRC, particularly in dMMR-MSI-H patients, but challenges and hurdles still exist. Further research on novel biomarkers and molecular signatures is needed to improve the effectiveness of immunotherapy in CRC treatment.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Oncology
Ling Wang, Shixu Li, Jun Mei, Lin Ye
Summary: Retinoblastoma is the most common intraocular tumor in children. Chemotherapy is the main method of treatment currently, but immunotherapy has become a new strategy. This article summarizes several potential targets for retinoblastoma immunotherapy and discusses the corresponding techniques and feasibility.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Lidia Sanchez-Moral, Tony Paul, Clara Martori, Joan Font-Diaz, Lucia Sanjurjo, Gemma Aran, Erica Tellez, Julia Blanco, Jorge Carrillo, Masaoki Ito, Martina Tuttolomondo, Henrik J. Ditzel, Caterina Fumagalli, Gustavo Tapia, Julia Sidorova, Helena Masnou, Marco-Antonio Fernandez-Sanmartin, Juan-Jose Lozano, Cristina Vilaplana, Alheli Rodriguez-Cortes, Carolina Armengol, Annabel F. Valledor, Leonor Kremer, Maria-Rosa Sarriasa
Summary: This study explores the role of macrophage CD5L protein in tumor-associated macrophage (TAM) activity and its potential as a therapeutic target. Results show that cancer cell lines induce an immunosuppressive phenotype in macrophages through increased CD5L expression. High TAM expression of CD5L is associated with poor patient outcomes in lung adenocarcinoma. Researchers developed an anti-CD5L monoclonal antibody that blocks the immunosuppressive phenotype in macrophages and inhibits tumor progression in vivo.
Review
Biochemistry & Molecular Biology
Antonio G. Solimando, Markus Krebs, Vanessa Desantis, Donatello Marziliano, Ingrid Catalina Caradonna, Arcangelo Morizio, Antonella Argentiero, Endrit Shahini, Max Bittrich
Summary: Multiple myeloma (MM) is a cancerous condition characterized by the proliferation of plasma cells in the bone marrow, leading to multiple bone lesions. Over the past two decades, significant advancements have been made in the development of novel therapeutics for MM, improving patient outcomes and overall survival. These advancements include thalidomide and its derivatives, proteasome inhibitors, monoclonal antibodies, and CAR-T-based strategies, which target neoplastic plasma cells and the tumor microenvironment.
Article
Oncology
Charles L. Vogel, Melody A. Cobleigh, Debu Tripathy, John C. Gutheil, Lyndsay N. Harris, Louis Fehrenbacher, Dennis J. Slamon, Maureen Murphy, William F. Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart, Michael Press
Summary: The purpose of this study was to evaluate the efficacy and safety of single-agent trastuzumab as first-line treatment in women with HER2-positive metastatic breast cancer. The results showed that single-agent trastuzumab had good efficacy and tolerability in the treatment of HER2-positive metastatic breast cancer.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Materials Science, Multidisciplinary
Amir Erfani, Antonio E. Diaz, Patrick S. Doyle
Summary: Over the past decade, immunotherapy interventions have revolutionized oncology and autoimmune disease fields. Researchers are developing new platforms for immunotherapy that go beyond intravenous delivery strategies. Recent advances include using chemokines to direct immune cells, alternative therapies, and oncolytic viruses. Hydrogel-based materials show promise for diverse biomedical applications, including large molecule drug delivery. Local hydrogel delivery is a promising approach to increase the efficacy and decrease toxicities of immunotherapies. Challenges remain in the translation of hydrogels to the clinic and manufacturing.
Article
Oncology
Cagla Kayabasi, Ayse Caner, Sunde Yilmaz Susluer, Tugce Balci Okcanoglu, Besra Ozmen Yelken, Aycan Asik, Zeynep Mutlu, Cansu Caliskan Kurt, Bakiye Goker Bagca, Cigir Biray Avci, Fahri Sahin, Guray Saydam, Cumhur Gunduz
Summary: LncRNAs are involved in the treatment of chronic myeloid leukemia (CML) with dasatinib and ponatinib. Dasatinib and ponatinib re-regulate lncRNA expressions in CML cells, affecting their survival and proliferation abilities. Ponatinib is more effective than dasatinib in inducing CML cell apoptosis and inhibiting proliferation.
Article
Oncology
Bakiye Goker Bagca, Cigir Biray Avci, Baha Sezgin, Ali Veral, Sercan Gode, Halil Bulent Karci
Summary: This study aimed to investigate the role of the WNT signaling pathway in maxillary sinus tumors. Through gene expression analysis and protein-protein interaction network analysis, changes in regulatory genes of the pathway were identified in the cancer. The results suggest that the pathway may play an important role in the development of maxillary sinus carcinoma. These findings contribute to a better understanding of the genetic regulation of this rare cancer and provide insights for further research on potential therapeutic targets of the WNT signaling pathway.
Article
Oncology
Selin Cesmeli, Bakiye Goker Bagca, Hasan Onur Caglar, Neslihan Pinar Ozates, Cumhur Gunduz, Cigir Biray Avci
Summary: Resveratrol and BIBR1532, either alone or in combination, can reduce the viability of colorectal cancer cells by repressing the expression of LncRNAs associated with the progression of colorectal cancer.
Article
Oncology
Buket Ozel, Sezgi Kipcak, Cigir Biray Avci, Cumhur Gunduz, Guray Saydam, Cagdas Aktan, Nur Selvi Gunel
Summary: This study investigated the effects of dasatinib and okadaic acid on apoptosis and cell cycle arrest in the K562 cell line. The results showed that the combination of dasatinib and okadaic acid increased apoptosis and caused cell cycle arrest. The enzyme activity of PP2A was decreased after dasatinib application, and the protein levels of PP2A were also reduced.
Review
Biochemistry & Molecular Biology
Behrouz Shademan, Alireza Nourazarian, Saba Hajazimian, Alireza Isazadeh, Cigir Biray Avci, Mahin Ahangar Oskouee
Summary: This article discusses the application of CRISPR technology in the detection and treatment of SARS-CoV-2 infection, as well as potential issues that may arise in the use of CRISPR/Cas technology.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)
Article
Engineering, Biomedical
Ecem Saygili, Utku Devamoglu, Bakiye Goker-Bagca, Ozlem Goksel, Cigir Biray-Avci, Tuncay Goksel, Ozlem Yesil-Celiktas
Summary: A multicellular spheroid model incorporating human bronchial epithelial cells and human lung fibroblasts was generated and treated with bleomycin to mimic drug-induced pulmonary fibrosis. The findings successfully reflected the fibrotic disease and provided insights into the underlying mechanism of fibrosis.
BIOMEDICAL MATERIALS
(2022)
Review
Biochemistry & Molecular Biology
Aysa Rezabakhsh, Mahdi Mahdipour, Alireza Nourazarian, Paria Habibollahi, Emel Sokullu, Cigir Biray Avci, Reza Rahbarghazi
Summary: The COVID-19 pandemic has caused global concern and the lack of effective medications and vaccines, as well as the emergence of resistant strains, have led to worsening public health. Exosomes, nanosized vesicles, have therapeutic properties and can transfer biomolecules and anti-inflammatory cytokines, potentially playing a role in alleviating COVID-19 pathologies.
CELL BIOCHEMISTRY AND FUNCTION
(2022)
Correction
Oncology
Bakiye Goker Bagca, Cigir Biray Avci, Baha Sezgin, Ali Veral, Sercan Gode, Halil Bulent Karci
Review
Chemistry, Multidisciplinary
Ilgin Kimiz-Gebologlu, Suphi S. Oncel
Summary: This review discusses the general properties and biological functions of exosomes, as well as their potential in drug delivery systems. It provides an overview of methods for large-scale production, isolation, and drug loading of exosomes, and investigates the current challenges and potential directions in this emerging field of drug delivery.
JOURNAL OF CONTROLLED RELEASE
(2022)
Article
Biochemistry & Molecular Biology
Cansu Tatar, Cigir Biray Avci, Eda Acikgoz, Gulperi Oktem
Summary: This study aims to investigate the effects of senescence induction on prostate cancer stem cells (CSCs). The results showed that Doxorubicin (DOX) is a potent inducer of senescence for prostate CSCs, inhibiting proliferation by arresting the cell cycle, and senescent prostate CSCs develop resistance to apoptosis.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Pathology
Merve Ozdemir, Berrin Ozdil, Cemile Sinem Asker Abdikan, Derya Erisik, Taha Kadir Yesin, Cigir Biray Avci, Yesim Kurkutcu, Gunnur Guler, Huseyin Aktug
Summary: Melanoma is a highly aggressive tumor with poor prognosis that can worsen during the metastatic phase. This study investigates the role of epigenetic mechanisms and cancer stem cells in melanoma progression, and suggests that targeting epigenetic modifications may be a promising treatment strategy. The study compares the levels of p300, HDAC9, and Factin proteins in different cell populations and explores their association with cell migration and division rates. The findings shed light on the molecular basis of melanoma initiation and progression, and contribute to the future management of metastatic diseases.
PATHOLOGY RESEARCH AND PRACTICE
(2023)
Article
Chemistry, Inorganic & Nuclear
Sifa Dogan, Mine Ince, Fatma Sogutlu, Cigir Biray Avci, Derya Ozel, Fatma Yurt
Summary: This study investigates the efficacy of photodynamic therapy (PDT) on triple-negative breast cancer (TNBC) cells and finds that PDT can effectively reduce the survival ability of TNBC cells and induce their apoptosis. The activation of phthalocyanine derivative with specific dose of red light enhances the effect of PDT.
Article
Oncology
Ecem Turkmen, Fatma Sogutlu, Mehmet Erdogan, Cigir Biray Avci
Summary: Treatment with BIBR1532 in ATC cells leads to increased apoptosis, cell cycle arrest, and decreased cell migration. This treatment upregulates the expression of BAD, BAX, CASP8, CYCS, TNFSF10, and CDKN2A genes, and downregulates the expression of BCL2L11, XIAP, and CCND2 genes. Additionally, BIBR1532 increases the expression of BAX and p16 proteins, while decreasing the concentration of BCL-2 protein. Therefore, targeting TERT with BIBR1532 as a mono drug or priming treatment before chemotherapy may offer a novel and promising therapeutic strategy for ATC.
Article
Oncology
Bakiye Goker Bagca, Neslihan Pinar Ozates, Cigir Biray Avci
Summary: This study evaluates the potential of ruxolitinib in treating glioblastoma, showing a synergistic effect when combined with temozolomide in inhibiting cancer cells and brain cancer stem cells. The study also finds that ruxolitinib can regulate the WNT signaling pathway, potentially enhancing the efficacy of temozolomide by affecting multiple signaling pathways.
Article
Oncology
Nur Selvi Gunel, Nuri Yildirim, Neslihan Pinar Ozates, Latife Merve Oktay, Bakiye Goker Bagca, Fatma Sogutlu, Aydin Ozsaran, Mehmet Korkmaz, Cigir Biray Avci
Summary: This study investigates the therapeutic potential of boron-containing DPD in epithelial ovarian cancer cells and its effects on the PI3K/AKT/mTOR pathway. The results suggest that DPD has anti-cancer properties, inducing apoptosis and affecting gene expressions associated with the pathway. This highlights the potential of DPD as a candidate compound in combination with chemotherapeutics.
